The Impact of SARS-CoV-2 Pandemic on Time to Primary, Secondary Resection and Adjuvant Intravesical Therapy in Patients with High-Risk Non-Muscle Invasive Bladder Cancer: A Retrospective Multi-Institutional Cohort Analysis
Background: To investigate the impact of COVID-19 outbreak on the diagnosis and treatment of non-muscle invasive bladder cancer (NMIBC). Methods: A retrospective analysis was performed using an Italian multi-institutional database of TURBT patients with high-risk urothelial NMIBC between January 201...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
MDPI AG
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/b269446779574f8987de160ab9c969df |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:b269446779574f8987de160ab9c969df |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:b269446779574f8987de160ab9c969df2021-11-11T15:26:54ZThe Impact of SARS-CoV-2 Pandemic on Time to Primary, Secondary Resection and Adjuvant Intravesical Therapy in Patients with High-Risk Non-Muscle Invasive Bladder Cancer: A Retrospective Multi-Institutional Cohort Analysis10.3390/cancers132152762072-6694https://doaj.org/article/b269446779574f8987de160ab9c969df2021-10-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/21/5276https://doaj.org/toc/2072-6694Background: To investigate the impact of COVID-19 outbreak on the diagnosis and treatment of non-muscle invasive bladder cancer (NMIBC). Methods: A retrospective analysis was performed using an Italian multi-institutional database of TURBT patients with high-risk urothelial NMIBC between January 2019 and February 2021, followed by Re-TURBT and/or adjuvant intravesical BCG. Results: A total of 2591 patients from 27 institutions with primary TURBT were included. Of these, 1534 (59.2%) and 1056 (40.8%) underwent TURBT before and during the COVID-19 outbreak, respectively. Time between diagnosis and TURBT was significantly longer during the COVID-19 period (65 vs. 52 days, <i>p</i> = 0.002). One thousand and sixty-six patients (41.1%) received Re-TURBT, 604 (56.7%) during the pre-COVID-19. The median time to secondary resection was significantly longer during the COVID-19 period (55 vs. 48 days, <i>p</i> < 0.0001). A total of 977 patients underwent adjuvant intravesical therapy after primary or secondary resection, with a similar distribution across the two groups (<i>n</i> = 453, 86% vs. <i>n</i> = 388, 86.2%). However, the proportion of the patients who underwent maintenance significantly differed (79.5% vs. 60.4%, <i>p</i> < 0.0001). Conclusions: The COVID-19 pandemic represented an unprecedented challenge to our health system. Our study did not show significant differences in TURBT quality. However, a delay in treatment schedule and disease management was observed. Investigation of the oncological impacts of those differences should be advocated.Matteo FerroFrancesco Del GiudiceGiuseppe CarrieriGian Maria BusettoLuigi CormioRodolfo HurleRoberto ContieriDavide ArcanioloAlessandro SciarraMartina MaggiFrancesco PorpigliaMatteo ManfrediCristian FioriAlessandro AntonelliAlessandro TafuriPierluigi BoveCarlo TerroneMarco BorghesiElisabetta CostantiniEster IlianoEmanuele MontanariLuca BoeriGiorgio Ivan RussoMassimo MadoniaAlessandro TeddeAlessandro VecciaClaudio SimeoneGiovanni LiguoriCarlo TrombettaEugenio BrunocillaRiccardo SchiavinaFabrizio Dal MoroMarco RacioppiMihai Dorin VartolomeiNicola LongoLorenzo SpiritoFelice CrocettoFrancesco CantielloRocco DamianoSavino M. Di StasiMichele MarchioniLuigi SchipsPaolo ParmaLuca CarmignaniAndrea ContiFrancesco SoriaPaolo GonteroBiagio BaroneFederico DehoEmanuele ZaffutoRocco PapaliaRoberto M. ScarpaVincenzo PagliaruloGiuseppe LucarelliPasquale DitonnoFrancesco Maria Gerardo BotticelliGennaro MusiMichele CatellaniOttavio de CobelliMDPI AGarticlebladder cancerSARS-CoV-2intravesical BCGtrans-urethral resection of bladder tumorRe-TURBTNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5276, p 5276 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
bladder cancer SARS-CoV-2 intravesical BCG trans-urethral resection of bladder tumor Re-TURBT Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 |
| spellingShingle |
bladder cancer SARS-CoV-2 intravesical BCG trans-urethral resection of bladder tumor Re-TURBT Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Matteo Ferro Francesco Del Giudice Giuseppe Carrieri Gian Maria Busetto Luigi Cormio Rodolfo Hurle Roberto Contieri Davide Arcaniolo Alessandro Sciarra Martina Maggi Francesco Porpiglia Matteo Manfredi Cristian Fiori Alessandro Antonelli Alessandro Tafuri Pierluigi Bove Carlo Terrone Marco Borghesi Elisabetta Costantini Ester Iliano Emanuele Montanari Luca Boeri Giorgio Ivan Russo Massimo Madonia Alessandro Tedde Alessandro Veccia Claudio Simeone Giovanni Liguori Carlo Trombetta Eugenio Brunocilla Riccardo Schiavina Fabrizio Dal Moro Marco Racioppi Mihai Dorin Vartolomei Nicola Longo Lorenzo Spirito Felice Crocetto Francesco Cantiello Rocco Damiano Savino M. Di Stasi Michele Marchioni Luigi Schips Paolo Parma Luca Carmignani Andrea Conti Francesco Soria Paolo Gontero Biagio Barone Federico Deho Emanuele Zaffuto Rocco Papalia Roberto M. Scarpa Vincenzo Pagliarulo Giuseppe Lucarelli Pasquale Ditonno Francesco Maria Gerardo Botticelli Gennaro Musi Michele Catellani Ottavio de Cobelli The Impact of SARS-CoV-2 Pandemic on Time to Primary, Secondary Resection and Adjuvant Intravesical Therapy in Patients with High-Risk Non-Muscle Invasive Bladder Cancer: A Retrospective Multi-Institutional Cohort Analysis |
| description |
Background: To investigate the impact of COVID-19 outbreak on the diagnosis and treatment of non-muscle invasive bladder cancer (NMIBC). Methods: A retrospective analysis was performed using an Italian multi-institutional database of TURBT patients with high-risk urothelial NMIBC between January 2019 and February 2021, followed by Re-TURBT and/or adjuvant intravesical BCG. Results: A total of 2591 patients from 27 institutions with primary TURBT were included. Of these, 1534 (59.2%) and 1056 (40.8%) underwent TURBT before and during the COVID-19 outbreak, respectively. Time between diagnosis and TURBT was significantly longer during the COVID-19 period (65 vs. 52 days, <i>p</i> = 0.002). One thousand and sixty-six patients (41.1%) received Re-TURBT, 604 (56.7%) during the pre-COVID-19. The median time to secondary resection was significantly longer during the COVID-19 period (55 vs. 48 days, <i>p</i> < 0.0001). A total of 977 patients underwent adjuvant intravesical therapy after primary or secondary resection, with a similar distribution across the two groups (<i>n</i> = 453, 86% vs. <i>n</i> = 388, 86.2%). However, the proportion of the patients who underwent maintenance significantly differed (79.5% vs. 60.4%, <i>p</i> < 0.0001). Conclusions: The COVID-19 pandemic represented an unprecedented challenge to our health system. Our study did not show significant differences in TURBT quality. However, a delay in treatment schedule and disease management was observed. Investigation of the oncological impacts of those differences should be advocated. |
| format |
article |
| author |
Matteo Ferro Francesco Del Giudice Giuseppe Carrieri Gian Maria Busetto Luigi Cormio Rodolfo Hurle Roberto Contieri Davide Arcaniolo Alessandro Sciarra Martina Maggi Francesco Porpiglia Matteo Manfredi Cristian Fiori Alessandro Antonelli Alessandro Tafuri Pierluigi Bove Carlo Terrone Marco Borghesi Elisabetta Costantini Ester Iliano Emanuele Montanari Luca Boeri Giorgio Ivan Russo Massimo Madonia Alessandro Tedde Alessandro Veccia Claudio Simeone Giovanni Liguori Carlo Trombetta Eugenio Brunocilla Riccardo Schiavina Fabrizio Dal Moro Marco Racioppi Mihai Dorin Vartolomei Nicola Longo Lorenzo Spirito Felice Crocetto Francesco Cantiello Rocco Damiano Savino M. Di Stasi Michele Marchioni Luigi Schips Paolo Parma Luca Carmignani Andrea Conti Francesco Soria Paolo Gontero Biagio Barone Federico Deho Emanuele Zaffuto Rocco Papalia Roberto M. Scarpa Vincenzo Pagliarulo Giuseppe Lucarelli Pasquale Ditonno Francesco Maria Gerardo Botticelli Gennaro Musi Michele Catellani Ottavio de Cobelli |
| author_facet |
Matteo Ferro Francesco Del Giudice Giuseppe Carrieri Gian Maria Busetto Luigi Cormio Rodolfo Hurle Roberto Contieri Davide Arcaniolo Alessandro Sciarra Martina Maggi Francesco Porpiglia Matteo Manfredi Cristian Fiori Alessandro Antonelli Alessandro Tafuri Pierluigi Bove Carlo Terrone Marco Borghesi Elisabetta Costantini Ester Iliano Emanuele Montanari Luca Boeri Giorgio Ivan Russo Massimo Madonia Alessandro Tedde Alessandro Veccia Claudio Simeone Giovanni Liguori Carlo Trombetta Eugenio Brunocilla Riccardo Schiavina Fabrizio Dal Moro Marco Racioppi Mihai Dorin Vartolomei Nicola Longo Lorenzo Spirito Felice Crocetto Francesco Cantiello Rocco Damiano Savino M. Di Stasi Michele Marchioni Luigi Schips Paolo Parma Luca Carmignani Andrea Conti Francesco Soria Paolo Gontero Biagio Barone Federico Deho Emanuele Zaffuto Rocco Papalia Roberto M. Scarpa Vincenzo Pagliarulo Giuseppe Lucarelli Pasquale Ditonno Francesco Maria Gerardo Botticelli Gennaro Musi Michele Catellani Ottavio de Cobelli |
| author_sort |
Matteo Ferro |
| title |
The Impact of SARS-CoV-2 Pandemic on Time to Primary, Secondary Resection and Adjuvant Intravesical Therapy in Patients with High-Risk Non-Muscle Invasive Bladder Cancer: A Retrospective Multi-Institutional Cohort Analysis |
| title_short |
The Impact of SARS-CoV-2 Pandemic on Time to Primary, Secondary Resection and Adjuvant Intravesical Therapy in Patients with High-Risk Non-Muscle Invasive Bladder Cancer: A Retrospective Multi-Institutional Cohort Analysis |
| title_full |
The Impact of SARS-CoV-2 Pandemic on Time to Primary, Secondary Resection and Adjuvant Intravesical Therapy in Patients with High-Risk Non-Muscle Invasive Bladder Cancer: A Retrospective Multi-Institutional Cohort Analysis |
| title_fullStr |
The Impact of SARS-CoV-2 Pandemic on Time to Primary, Secondary Resection and Adjuvant Intravesical Therapy in Patients with High-Risk Non-Muscle Invasive Bladder Cancer: A Retrospective Multi-Institutional Cohort Analysis |
| title_full_unstemmed |
The Impact of SARS-CoV-2 Pandemic on Time to Primary, Secondary Resection and Adjuvant Intravesical Therapy in Patients with High-Risk Non-Muscle Invasive Bladder Cancer: A Retrospective Multi-Institutional Cohort Analysis |
| title_sort |
impact of sars-cov-2 pandemic on time to primary, secondary resection and adjuvant intravesical therapy in patients with high-risk non-muscle invasive bladder cancer: a retrospective multi-institutional cohort analysis |
| publisher |
MDPI AG |
| publishDate |
2021 |
| url |
https://doaj.org/article/b269446779574f8987de160ab9c969df |
| work_keys_str_mv |
AT matteoferro theimpactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT francescodelgiudice theimpactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT giuseppecarrieri theimpactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT gianmariabusetto theimpactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT luigicormio theimpactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT rodolfohurle theimpactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT robertocontieri theimpactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT davidearcaniolo theimpactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT alessandrosciarra theimpactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT martinamaggi theimpactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT francescoporpiglia theimpactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT matteomanfredi theimpactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT cristianfiori theimpactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT alessandroantonelli theimpactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT alessandrotafuri theimpactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT pierluigibove theimpactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT carloterrone theimpactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT marcoborghesi theimpactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT elisabettacostantini theimpactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT esteriliano theimpactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT emanuelemontanari theimpactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT lucaboeri theimpactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT giorgioivanrusso theimpactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT massimomadonia theimpactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT alessandrotedde theimpactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT alessandroveccia theimpactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT claudiosimeone theimpactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT giovanniliguori theimpactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT carlotrombetta theimpactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT eugeniobrunocilla theimpactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT riccardoschiavina theimpactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT fabriziodalmoro theimpactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT marcoracioppi theimpactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT mihaidorinvartolomei theimpactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT nicolalongo theimpactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT lorenzospirito theimpactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT felicecrocetto theimpactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT francescocantiello theimpactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT roccodamiano theimpactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT savinomdistasi theimpactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT michelemarchioni theimpactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT luigischips theimpactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT paoloparma theimpactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT lucacarmignani theimpactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT andreaconti theimpactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT francescosoria theimpactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT paologontero theimpactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT biagiobarone theimpactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT federicodeho theimpactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT emanuelezaffuto theimpactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT roccopapalia theimpactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT robertomscarpa theimpactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT vincenzopagliarulo theimpactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT giuseppelucarelli theimpactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT pasqualeditonno theimpactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT francescomariagerardobotticelli theimpactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT gennaromusi theimpactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT michelecatellani theimpactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT ottaviodecobelli theimpactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT matteoferro impactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT francescodelgiudice impactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT giuseppecarrieri impactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT gianmariabusetto impactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT luigicormio impactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT rodolfohurle impactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT robertocontieri impactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT davidearcaniolo impactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT alessandrosciarra impactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT martinamaggi impactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT francescoporpiglia impactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT matteomanfredi impactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT cristianfiori impactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT alessandroantonelli impactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT alessandrotafuri impactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT pierluigibove impactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT carloterrone impactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT marcoborghesi impactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT elisabettacostantini impactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT esteriliano impactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT emanuelemontanari impactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT lucaboeri impactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT giorgioivanrusso impactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT massimomadonia impactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT alessandrotedde impactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT alessandroveccia impactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT claudiosimeone impactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT giovanniliguori impactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT carlotrombetta impactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT eugeniobrunocilla impactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT riccardoschiavina impactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT fabriziodalmoro impactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT marcoracioppi impactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT mihaidorinvartolomei impactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT nicolalongo impactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT lorenzospirito impactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT felicecrocetto impactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT francescocantiello impactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT roccodamiano impactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT savinomdistasi impactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT michelemarchioni impactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT luigischips impactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT paoloparma impactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT lucacarmignani impactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT andreaconti impactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT francescosoria impactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT paologontero impactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT biagiobarone impactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT federicodeho impactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT emanuelezaffuto impactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT roccopapalia impactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT robertomscarpa impactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT vincenzopagliarulo impactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT giuseppelucarelli impactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT pasqualeditonno impactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT francescomariagerardobotticelli impactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT gennaromusi impactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT michelecatellani impactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis AT ottaviodecobelli impactofsarscov2pandemicontimetoprimarysecondaryresectionandadjuvantintravesicaltherapyinpatientswithhighrisknonmuscleinvasivebladdercanceraretrospectivemultiinstitutionalcohortanalysis |
| _version_ |
1718435328912523264 |